Patient Leaflet Updated 20-Apr-2021 | Ranbaxy (UK) Limited a Sun Pharmaceutical Company
Fulvestrant SUN 250 mg solution for injection in pre-filled syringe
Fulvestrant 250 mg solution for injection in pre-filled syringe
fulvestrant
1. What Fulvestrant is and what it is used for
2. What you need to know before you are given Fulvestrant
3. How Fulvestrant will be given
4. Possible side effects
5. How to store Fulvestrant
6. Contents of the pack and other information
Fulvestrant contains the active substance fulvestrant, which belongs to the group of estrogen blockers. Estrogens, a type of female sex hormones, can in some cases be involved in the growth of breast cancer.
Fulvestrant is used either:
When Fulvestrant is given in combination with palbociclib, it is important that you also read the package leaflet for palbociclib. If you have any questions about palbociclib, please ask your doctor.
Talk to your doctor or pharmacist or nurse before being treated with Fulvestrant if any of these apply to you:
Fulvestrant is not for use in children and adolescents under 18 years.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, you should tell your doctor if you are taking:
You must not be given Fulvestrant if you are pregnant. If you can become pregnant, you should use effective contraception while are being treated with Fulvestrant and for 2 years after your last dose.
You must not breast-feed while on treatment with Fulvestrant.
Fulvestrant is not expected to affect your ability to drive or use machines. However, if you feel tired after treatment do not drive or use machines.
Fulvestrant contains 10% w/v ethanol (alcohol), i.e. up to 1 g per dose, equivalent to 20 ml beer or 8 ml wine per dose. Harmful for those suffering from alcoholism.
To be taken into account in pregnant or breast-feeding women and high-risk groups such as patients with liver disease, or epilepsy.
Fulvestrant contains castor oil, which may cause severe allergic reactions.
This medicine contains 1 g benzyl alcohol in each dose which is equivalent to 100 mg/ml. Benzyl alcohol may cause allergic reactions.
Ask your doctor or pharmacist for advice if you are pregnant or breast-feeding or if you have a liver or kidney disease. This is because large amounts of benzyl alcohol can build-up in your body and may cause side effects (called “metabolic acidosis”).
Your doctor or nurse will give you Fulvestrant as a slow intramuscular injection, one into each of your buttocks.
The recommended dose is 500 mg fulvestrant (two 250 mg/5 ml injections) given once a month, with an additional 500 mg dose given 2 weeks after the initial dose.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor immediately if you experience any of the following side effects
Tell your doctor, pharmacist or nurse if you notice any of the following
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
* Includes side effects for which the exact role of Fulvestrant cannot be assessed due to the underlying disease.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and syringe labels after EXP. The expiry date refers to the last day of that month.
Store and transport refrigerated (2°C - 8°C).
Temperature excursions outside 2°C to 8°C should be limited. This includes avoiding storage at temperatures exceeding 30°C, and not exceeding a 28 day period where the average storage temperature for the product is below 25°C (but above 2°C to 8°C). After temperature excursions, the product should be returned immediately to the recommended storage conditions (store and transport in a refrigerator 2°C to 8°C). Temperature excursions have a cumulative effect on the product quality and the 28 day time period must not be exceeded over the duration of the shelf life of Fulvestrant
Exposure to temperatures below 2°C will not damage the product providing it is not stored below -20°C.
Store the pre-filled syringe in the original package, in order to protect from light.
Your healthcare professional will be responsible for the correct storage, use and disposal of Fulvestrant.
This medicine may pose a risk to the aquatic environment. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Fulvestrant is a clear, colourless to yellow, viscous solution in a pre-filled syringe fitted with a tamper-evident closure, containing 5 ml solution for injection. Two syringes must be administered to receive the 500 mg recommended monthly dose.
Fulvestrant has 4 pack presentations, consisting of packs containing 1, 2, 4 or 6 glass pre-filled syringe(s). 1, 2, 4 or 6 safety needle(s) (BD SafetyGlide) for connection to each barrel are also provided.
Not all pack sizes may be marketed.
This medicinal product is authorised in the Member States of the EEA under the following names:
Denmark Fulvestrant SUN
Germany Fulvestrant SUN
France Fulvestrant SUN
Italy Fulvestrant SUN
The Netherlands Fulvestrant SUN
Norway Fulvestrant SUN
Poland Fulvestrant SUN
Romania Fulvestrant SUN
Spain Fulvestrant SUN
Sweden Fulvestrant SUN
United Kingdom Fulvestrant SUN
This leaflet was last revised in September 2020
V004
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW, UK
+44 (0) 208 848 5052